Safety, immunogenicity, and efficacy of an alphavirus replicon-based swine influenza virus hemagglutinin vaccine

Ryan L. Vander Veen, Alan T. Loynachan, Mark A. Mogler, Brandon J. Russell, D. L.Hank Harris, Kurt I. Kamrud

Research output: Contribution to journalArticlepeer-review

52 Scopus citations

Abstract

A single-cycle, propagation-defective replicon particle (RP) vaccine expressing a swine influenza virus hemagglutinin (HA) gene was constructed and evaluated in several different animal studies. Studies done in both the intended host (pigs) and non-host (mice) species demonstrated that the RP vaccine is not shed or spread by vaccinated animals to comingled cohorts, nor does it revert to virulence following vaccination. In addition, vaccinated pigs develop both specific humoral and IFN-γ immune responses, and young pigs are protected against homologous influenza virus challenge.

Original languageEnglish
Pages (from-to)1944-1950
Number of pages7
JournalVaccine
Volume30
Issue number11
DOIs
StatePublished - Mar 2 2012

Keywords

  • Alphavirus replicon
  • Hemagglutinin (HA)
  • Safety
  • Swine
  • Swine influenza virus (SIV)
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • General Immunology and Microbiology
  • General Veterinary
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Safety, immunogenicity, and efficacy of an alphavirus replicon-based swine influenza virus hemagglutinin vaccine'. Together they form a unique fingerprint.

Cite this